tetano
Editor, Senior Moderator
Open Forum Infect Dis
. 2024 Jan 3;11(2)
fad673.
doi: 10.1093/ofid/ofad673. eCollection 2024 Feb. Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Subvariant Neutralization Following a Primary Vaccine Series of NVX-CoV2373 and BNT162b2 Monovalent Booster Vaccine
Tara M Babu[SUP] 1 [/SUP], Xiaoying Shen[SUP] 2 [/SUP], R Scott McClelland[SUP] 1 3 4 [/SUP], Zijun Wang[SUP] 5 [/SUP], Stacy Selke[SUP] 1 [/SUP], Chloe Wilkens[SUP] 1 [/SUP], Kirsten A Hauge[SUP] 1 [/SUP], Christopher L McClurkan[SUP] 1 [/SUP], Erin Goecker[SUP] 1 [/SUP], Kerry J Laing[SUP] 1 [/SUP], David M Koelle[SUP] 1 3 6 7 8 [/SUP], Alexander L Greninger[SUP] 6 7 [/SUP], Michel C Nussenzweig[SUP] 5 9 [/SUP], David C Montefiori[SUP] 2 10 [/SUP], Lawrence Corey[SUP] 1 6 7 [/SUP], Anna Wald[SUP] 1 4 6 7 [/SUP]
Affiliations
We evaluated the immunologic response to a novel vaccine regimen that included 2 doses of NVX-CoV2373 (Novavax) followed by 1 dose of BNT162b2 (Pfizer-BioNTech) monovalent booster vaccine. A durable neutralizing antibody response to Omicron BA.4/BA.5 and BA.1 variants was observed at month 6 after the booster, while immune escape was noted for the XBB.1.5 variant.
Keywords: SARS-CoV-2; antibody; vaccine; virus.
. 2024 Jan 3;11(2)
fad673.doi: 10.1093/ofid/ofad673. eCollection 2024 Feb. Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Subvariant Neutralization Following a Primary Vaccine Series of NVX-CoV2373 and BNT162b2 Monovalent Booster Vaccine
Tara M Babu[SUP] 1 [/SUP], Xiaoying Shen[SUP] 2 [/SUP], R Scott McClelland[SUP] 1 3 4 [/SUP], Zijun Wang[SUP] 5 [/SUP], Stacy Selke[SUP] 1 [/SUP], Chloe Wilkens[SUP] 1 [/SUP], Kirsten A Hauge[SUP] 1 [/SUP], Christopher L McClurkan[SUP] 1 [/SUP], Erin Goecker[SUP] 1 [/SUP], Kerry J Laing[SUP] 1 [/SUP], David M Koelle[SUP] 1 3 6 7 8 [/SUP], Alexander L Greninger[SUP] 6 7 [/SUP], Michel C Nussenzweig[SUP] 5 9 [/SUP], David C Montefiori[SUP] 2 10 [/SUP], Lawrence Corey[SUP] 1 6 7 [/SUP], Anna Wald[SUP] 1 4 6 7 [/SUP]
Affiliations
- PMID: 38379566
- PMCID: PMC10878050
- DOI: 10.1093/ofid/ofad673
We evaluated the immunologic response to a novel vaccine regimen that included 2 doses of NVX-CoV2373 (Novavax) followed by 1 dose of BNT162b2 (Pfizer-BioNTech) monovalent booster vaccine. A durable neutralizing antibody response to Omicron BA.4/BA.5 and BA.1 variants was observed at month 6 after the booster, while immune escape was noted for the XBB.1.5 variant.
Keywords: SARS-CoV-2; antibody; vaccine; virus.